Office Buildings Still Sit Empty in Major Metros

 

According to a report by the Wall Street Journal, the office return rate was up to 27% and climbing in mid-October. That number has since declined since COVID’S latest spike. Employees are back to working from home, and many corporations are reluctant to say whether they’ll be back anytime soon. This spells trouble for commercial real estate landlords. But even more tragically, small retail businesses are taking the hit, losing a large chunk of their business that comes from foot traffic from nearby office buildings.

Tyler Kern and Daniel Litwin, MarketScale Radio Hosts, consider the ripple effects of empty office space. Kern and Litwin look to the government’s weak financial response to the crisis as a culprit in the trickle down negative effects on businesses big and small.

KEY POINTS:

  • Urban centers still feel like ghost towns as COVID continues to spread.
  • Real estate landlords scramble and pressure the government for a full economic re-opening.
  • Small businesses in urban metros take the financial hit from empty office buildings.

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More